0 items
Your cart is empty.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
$131.00
This product is available by prescription only
This product does not require a prescription
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
The product is delivered in powdered (lyophilized) form and must be properly reconstituted prior to research use.
This synthetic research peptide formulation provides laboratories with a modified insulin-like growth factor compound for experimental studies. The compact 1mg format supports controlled research applications in qualified laboratory settings. Each batch undergoes rigorous purity verification to ensure consistency across research protocols. High-purity formulation meets research-grade standards for modified growth factor investigations. Secure packaging protects compound integrity during storage and transport. Discreet shipment ensures confidential delivery to research facilities and institutional laboratories.
Researchers investigate IGF-1 LR3 peptide within controlled laboratory environments to examine modified peptide structures and molecular mechanisms. Experimental cell culture models utilize this compound to study peptide analog characteristics in vitro. Controlled laboratory peptide stability studies assess compound properties under standardized experimental conditions. Scientists explore structural modifications and binding protein interactions in research settings. Laboratory personnel examine modified peptide behavior in experimental models designed for growth factor analog research. These investigations occur exclusively in controlled research environments without clinical applications.
IGF-1 LR3 is investigated in research environments to understand modified growth factor peptide mechanisms. This compound is studied within controlled laboratory models examining peptide analog properties. Researchers explore this peptide for experimental peptide research applications in academic and institutional settings. Laboratory studies examine the compound’s structural characteristics under standardized protocols. Scientists investigate molecular properties relevant to growth factor analog research methodologies. All research applications remain confined to laboratory environments and experimental frameworks.
Store IGF-1 LR3 peptide at -20°C for optimal long-term stability before reconstitution. Storage temperature should remain consistent to maintain compound integrity. Keep the product sealed until ready for laboratory use. Laboratory handling should occur only by qualified research personnel trained in peptide research protocols. Avoid exposure to moisture, heat, and direct sunlight during storage. Use appropriate laboratory equipment when handling this research compound. Reconstitution should follow standard laboratory peptide preparation procedures using sterile techniques. After reconstitution, store at 2-8°C according to institutional protocols. Maintain proper documentation of handling and storage conditions for research records. Dispose of unused material according to institutional laboratory waste protocols.
Each batch undergoes comprehensive purity verification procedures to confirm research-grade quality. Third-party testing validates compound purity at 99%+ by HPLC analysis. Batch-to-batch consistency ensures reliable results across research protocols. Certificate of Analysis accompanies each order documenting purity verification results. Internal quality assurance standards maintain strict compound specifications. Testing procedures verify molecular weight, purity percentage, structural modifications, and compound identity. Research-grade supply positioning ensures suitability for controlled laboratory investigations. Quality control documentation supports institutional research compliance requirements.
IGF-1 LR3 is a synthetic modified peptide analog compound produced for research applications. This peptide is a modified version of insulin-like growth factor with structural alterations. The modification includes additional amino acids creating an extended peptide chain. The “Long R3” designation refers to the specific structural modification present. Modified peptides are studied to understand how structural changes affect molecular properties. This analog demonstrates altered binding characteristics with binding proteins in experimental systems. This synthetic peptide origin ensures batch-to-batch consistency for research protocols. The compound consists of a defined amino acid sequence with specific modifications. Researchers examine this modified peptide’s properties within controlled laboratory conditions without therapeutic context.
Novera Research delivers high-quality research peptides developed under strict manufacturing and quality-control standards. Each product is carefully synthesized, tested, and handled to ensure consistency, reliability, and transparency for advanced research applications.
High-purity, research-grade peptide synthesis
Analytical testing to verify quality and composition
Consistent batch-to-batch performance
Batch identification on every vial for traceability
Stored and shipped under controlled conditions
Research-grade decapeptide signaling molecule formulated for experimental peptide pathway research in controlled laboratory environments.
Research-grade selective synthetic pentapeptide formulated for experimental peptide interaction research in controlled laboratory settings.
Research-grade synthetic peptide analog formulated for experimental metabolic pathway research in controlled laboratory environments.
A synthetic 44-amino acid analog of growth hormone-releasing hormone studied for pituitary receptor binding kinetics, GHRH pathway signaling dynamics, and downstream somatotropic axis marker activity in controlled preclinical models.
Research-grade synthetic dual-peptide formulation combining amylin analog and GLP-1 receptor agonist for dual-mechanism pathway studies and combination peptide research in controlled laboratory environments.
